Cancer drug combo shows promise but trial halted early
NCT ID NCT02982694
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 26 times
Summary
This study tested a combination of two drugs (atezolizumab and bevacizumab) in 46 people with advanced colorectal cancer that had stopped responding to standard chemotherapy and had a specific genetic signature called MSI-like. The goal was to see if the combination could shrink tumors. The trial was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fundación Investigación Clínico de Valencia
Valencia, Spain
-
Institut Català d'Oncologia
Barcelona, Spain
-
KU Leuven
Leuven, Belgium
-
Ospedale Niguarda CA Granda
Milan, Italy
-
Second University of Naples
Naples, Italy
-
The Netherlands Cancer Institute
Amsterdam, Netherlands
-
Vall d'Hebron Institute of Oncology
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.